The scientific activity of prof. Giorgio Maria Calori and his team includes studies recognized at European and international level for quality and innovation of content and on issues that depth for the activities of medical and scientific research very accurate in hospitals.
More than 200 publications with impact factor and recognized in particular Prof. Giorgio Maria Calori is Italian and European level the leading expert in the field of biotechnology in orthopedics, as President ESTROT.
He has made a major study of the drug economy on the use of growth factors in trauma entitled "Comparative analysis of the costs and cost / effectiveness of the treatment of non-unions posttraumatic persistent tibia with TA of the Iliac Crest or Osigraft (alpha Eptotermin , rhBMP-7 rh OP-1).
"Biotechnology in Orthopedics and Traumatology in have become an essential resource. It is therefore imperative - says the prof. Giorgio Maria Calori - update and adapt behavioral and legal regulations, while respecting the socio-economic needs. Periodically I organized conferences with leading experts, researchers and clinicians, representing the most important hospital institutions and European university to focus the scientific evidence gained through trials robust international research based on a rigorous analysis of prospective randomized clinical trials. I also organized round tables, plus the inherent legal and economic aspects, in which senior judges, lawyers, doctors, lawyers, economists, scholars and researchers from different backgrounds are compared from year to year with the representatives of regional institutions and national deputies to the strategic choices health. "
Prof. Calori also works as a lecturer with the School of the University of Milan and specialization focuses on the quality training to encourage new achievements in medical and scientific research.
"In our courses and conferences - says Prof. Calori - give updates on new techniques and the results of even the most recent international studies. With regard to the application of biotechnology in Orthopedics and Traumatology are many interesting results obtained and the study, but there are also numerous new goals to reach. That's why conferences like this are motivating and useful for an open, important, international know-how and exchange of views in favor of medical ethics and always ameliorative for patients of today and tomorrow. "
Prof. Heat over the years has identified the problems and the related remedies, which can make appropriate use of biotechnology in hospitals and universities, thereby proposing recommendations and rules of conduct useful to health professionals and warranty and safety for patients.
He works in the Lombardy Region for the identification of a specific DRG and appropriate for biotechnology, in order to be able to make a correct clinical monitoring and extremely establish the right economic consideration.
"Important are the results of a prospective randomized clinical trial performed on 120 selected cases of atrophic nonunion of the limbs, treated with the help of these new techniques, at the Gaetano Pini Orthopaedic Institute in collaboration with the University of Milan - says the prof. Heat - and the data from a multicenter European triennial published on Injury, tested scientific international reference, which involved several medical and scientific facilities in Italy, England, Belgium, Finland, Greece. There are shown the results of application of growth factors with stem cells and also of the association of the latter with growth factors; the latter topic is the subject of a twofold prospective randomized clinical trial, already approved by the Ethics Committee of the Gaetano Pini and still ongoing, about the application of biotechnology on injuries periprosthetic hip and knee, besides always a comparison of completion use for the atrophic nonunion of long bones. "
"The early data from already published in 2006 and are now finally confirmed the completion of the study of the Pines on nonunion with an index of healing statistically significant dell'86.7% this trial confirmed by international European attesting all'89.7% cure rate, that is, it is almost obtained with these new techniques, the same result can be obtained with the use of bone autoplastic taken from the patient (autologous) without incurring the complications connected to this. "
Among the issues on which the prof. Calori and his team specialize include:
bone regeneration to biotechnology;
nonunion and failures osteosynthesis;
bone grafts;
stem cells and the processes of preparation;
experiences and clinical application of growth factors in the treatment of nonunion and loss of bone,
in stabilizing vertebral
in prosthetic surgery,
prophylaxis for the femoral head necrosis.
"With biotechnology - says the prof. Heats - especially in prosthetic, may be obtained already excellent results. As part of the hip surgery very developed in the Division of Orthopaedic Surgery from me directly, and in the reviews of systems with periprosthetic bone loss, the use of biotechnology can avoid using bone from other locations of the patient . It is thus possible to reduce the time for action, to avoid further pain and discomfort to the patient related to the donor site and give more benefit and more guarantees to the patient. It will also be important to define the new DRG for biotechnology in prosthetic surgery revision, defining exactly what are the forms that can benefit, as already recognized, using the degrees GIR (Groups Italian Riprotesizzazione) of type 3 and 4 '.
For years Professor Calori he is also a need for an ethical and legal framework of biotechnology in Orthopedics and Traumatology in pharmaco-economic studies and for a comparison of the health care system and the pharmaceutical industry.
"Our hospital, the Institute Gaetano Pini, is in the front row - says Prof. Calori - as the vanguard in the application of biotechnology in Orthopaedics and Traumatology."
It has always been a promoter of events scientific training and discussion between different experts of the problem; is needed as soon as possible to encode the data available to be able to achieve an efficient organization of clinical care services.
"The Department of Orto-Traumatology, which brings together, on the inside, and coordinates all Chirurgie iperspecialistiche Institute, has the task of facilitating the proper access to these resources by implementing an efficient organizational strategy."
"Nowadays, biotechnology has in fact opened a new perspective of care."
"It is both a great hope and a wonderful opportunity, but to be able to effectively spread the clinical application to different care settings - said prof. Giorgio Maria Calori, Chief of the Division of Orthopaedic Surgery, Restorative and expert in risk management at the Institute Gaetano Pini, Chairman ESTROT - is necessary for compliance with three basic elements: a clear how to use clinically validated by the most recent results of evidence scientific; an appropriate legal framework, to induce the change or the development of standards, in a sector subject to rapid evolution; effective economic sustainability, based on studies of drug-economy, with the implementation of a strategy for the use of funds and resources actually available. "
"In order to pursue a medical ethics we must point out the organizational model in order to provide a sustainable medicine of high quality and safety for the patient. Serve shared guidelines for cost-effectiveness analysis at the national and let down in their organizational reality we're working at Italian and European level. The research, both clinical and laboratory applications, ranging preordained to the study based on actual requirements designed to clinical practice. Basic medical science is the comparison internationally. "
"It is therefore necessary a framework of Italian and European legal rule on the use of biotechnology and stem cells for applications in orthopedics and traumatology."
In this regard, Prof. Calori part at the Italian Society of Orthopaedics and Traumatology, the special Commission for Tissue Regeneration, which consists of clinical and jurists, has, as its main object, the monitoring of the correct use of biotechnology and processing application of recommendations based on a rigorous scientific analysis.
"I think a lot - said Professor Giorgio Maria Calori - in the beginning of Medicine Ethics Collaborative that sole objective must be the improvement of the quality of life for patients."
